chufangao/CTO huggingface dataset:
Clinical trial NCT02813902: A Trial of Polypodium Leucotomos in Preventing Skin Cancer and Its Precursors
Official title: A Pilot Trial of Polypodium Leucotomos in Preventing Skin Cancer and Its Precursors
Sponsor: Massachusetts General Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Lack of funding.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-07-31
Primary completion date: 2020-05-31
Completion date: 2020-05-31
Clinical trial NCT03542110: The Alirocumab for Stopping Atherosclerosis Progression in Saphenous Vein Grafts (ASAP-SVG) Pilot Trial
Official title: Effect of Alirocumab on Saphenous Vein Graft Atherosclerosis: The Alirocumab for Stopping Atherosclerosis Progression in Saphenous Vein Grafts (ASAP-SVG) Pilot Trial
Acronym: ASAP-SVG
Sponsor: Minneapolis Heart Institute Foundation (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Withdrawal of medication and funding support by Sponsor
Enrollment: 46.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-08-04
Primary completion date: 2020-06-30
Completion date: 2020-07-31
Plan to share individual participant data: NO
Clinical trial NCT03277482: Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer
Official title: A Phase 1 Study of Durvalumab, Tremelimumab and Radiotherapy in Recurrent Gynecologic Cancer
Sponsor: Dana-Farber Cancer Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Expansion cohort was not open
Enrollment: 16.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-06-01
Primary completion date: 2022-07-15
Completion date: 2022-07-15
Plan to share individual participant data: NO
Clinical trial NCT03954990: Treatment of Bacterial Vaginosis Prior to Active Labor and Infectious Morbidity
Official title: Treatment of Bacterial Vaginosis Prior to Active Labor and Infectious Morbidity: A Randomized Controlled Trial
Sponsor: The University of Texas Medical Branch, Galveston (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Lack of significance/futile study
Enrollment: 75.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-10-11
Primary completion date: 2022-09-26
Completion date: 2022-09-26
Clinical trial NCT00655876: Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer
Official title: A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients With Esophageal Cancer Who Are Treated Without Surgery
Sponsor: Radiation Therapy Oncology Group (NETWORK)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 344.0 (ACTUAL)
Number of arms: 2.0
Start date: 2008-06-30
Primary completion date: 2015-04-30
Completion date: 2022-05-20
Baseline population: Eligible patients
Limitations and caveats: After a United Kingdom trial failed to show a benefit for cetuximab, accrual was suspended and the 3rd planned interim analysis done. After discussions with the Data Monitoring Committee, the study permanently closed to accrual on 2/8/2013.
Clinical trial NCT03838731: Study in Cat-Allergic Patients With Asthma to Evaluate the Efficacy of a Single Dose of REGN1908-1909 to Reduce Bronchoconstriction Upon Cat Allergen Challenge
Official title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study in Cat-Allergic Patients With Asthma to Evaluate the Efficacy of a Single Dose of REGN1908-1909 to Reduce Bronchoconstriction Upon Cat Allergen Challenge
Sponsor: Regeneron Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 56.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-02-12
Primary completion date: 2019-12-21
Completion date: 2020-04-06
Plan to share individual participant data: YES
IPD sharing description: All IPD that underlie results in a publication
IPD time frame: Individual de-identified participant data will be made available once the indication has been approved by a regulatory body, if there is participant consent and there is not a reasonable likelihood of participant re-identification
IPD access criteria: Qualified researchers may request access to study documents (including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan) that support the methods and findings reported in a manuscript. Individual de-identified participant data will be made available once the indication has been approved by a regulatory body, if there is participant consent and there is not a reasonable likelihood of participant re-identification
Clinical trial NCT04620135: Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
Official title: A Single-masked, Randomized, Multi-center, Parallel-group, 4-week Study Evaluating the Efficacy and Safety of Once Daily Netarsudil Ophthalmic Solution 0.02% Compared to Twice Daily Ripasudil Hydrochloride Hydrate Ophthalmic Solution 0.4% in Japanese Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
Sponsor: Aerie Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 245.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-11-30
Primary completion date: 2021-07-09
Completion date: 2021-07-30
Plan to share individual participant data: NO
Clinical trial NCT03768726: Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder
Official title: 26-WEEK OPEN-LABEL EXTENSION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF FLEXIBLE DOSES OF ORAL ZIPRASIDONE IN CHILDREN AND ADOLESCENTS WITH BIPOLAR I DISORDER (MOST RECENT EPISODE MANIC)
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Pfizer has decided to perform the pre-specified final analysis at the current enrollment using a re-estimation of the sample size.
Enrollment: 23.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-12-21
Primary completion date: 2020-07-31
Completion date: 2020-07-31
Baseline population: The safety analysis set included all participants who took at least 1 dose of study medication in this open-label extension study.
Limitations and caveats: Prioritization of outcome measures per study team's discretion.
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT03837743: Safety and Efficacy Study of DUR-928 Topical Solution in Subjects With Plaque Psoriasis
Official title: A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Proof of Concept Comparison Study of the Safety and Efficacy of DUR-928 Topical Solution With Occlusion in Subjects With Mild to Moderate Plaque Psoriasis
Sponsor: Durect (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 25.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-02-21
Primary completion date: 2019-11-11
Completion date: 2020-05-20
Baseline population: Safety Population
Plan to share individual participant data: NO
Clinical trial NCT04329572: Efficacy and Safety of Hydroxychloroquine and Azithromycin for Patients With Moderate to Severe COVID-19
Official title: Open, Multicentric, Non Randomized, Exploratory Clinical Trial to Assess the Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Acute Respiratory Syndrome (COVID-19) Caused by SARS-CoV-2 Virus
Sponsor: Azidus Brasil (INDUSTRY)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: SUSPENDED 
Why stopped: Azidus, the CRO hired for this study by Prevent Senior has lost the interest to conduct this study.
Enrollment: 400.0 (ESTIMATED)
Number of arms: 1.0
Start date: 2020-04-23
Primary completion date: 2020-05-31
Completion date: 2023-06-30
Plan to share individual participant data: NO
IPD sharing description: It is believed that after the data analysis and presentation to the National Commission on Research Ethics, all data of the study will become public.
Clinical trial NCT03186638: Low-Dose Ibuprofen in Improving Cognitive Impairment in Patients With Cancer
Official title: Phase II Study of Low-Dose Ibuprofen for Cognitive Problems in Patients With Cancer
Sponsor: University of Rochester (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 87.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-05-26
Primary completion date: 2022-03-30
Completion date: 2022-06-01
Clinical trial NCT03380507: Evaluation of Hydrocortisone, Vitamin C and Thiamine for the Treatment of Septic Shock
Official title: Evaluation of Hydrocortisone, Vitamin C and Thiamine for the Treatment of Septic Shock
Acronym: HYVITS
Sponsor: Hamad Medical Corporation (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: The research is no longer funded and terminated due to futility
Enrollment: 106.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-03-17
Primary completion date: 2019-10-03
Completion date: 2021-11-01
Plan to share individual participant data: NO
Clinical trial NCT03814135: Efficacy and Safety of Two Doses of Hipnos in the Treatment of Adults With Insomnia
Official title: Randomized, Double-blind, Double-dummy, National, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Two Doses of Hipnos Medication in the Treatment of Adults With Insomnia
Sponsor: EMS (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Sponsor decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-01-31
Primary completion date: 2022-02-28
Completion date: 2022-03-31
Clinical trial NCT04492020: Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants
Official title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine When Administered During the Prodrome
Acronym: UBR Prodrome
Sponsor: AbbVie (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 518.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-08-21
Primary completion date: 2022-04-19
Completion date: 2022-04-19
Baseline population: Safety Population consists of all treated participants who take at least 1 administration of study intervention
Plan to share individual participant data: YES
IPD sharing description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
IPD time frame: For details on when studies are available for sharing, please refer to the link below
IPD access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.
Clinical trial NCT04343976: Pegylated Interferon Lambda Treatment for COVID-19
Official title: A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Pegylated Interferon Lambda vs. Placebo in Subjects Infected With COVID-19
Sponsor: Massachusetts General Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Unable to meet enrollment goal, lack of funding.
Enrollment: 14.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-06-22
Primary completion date: 2021-07-30
Completion date: 2021-07-30
Limitations and caveats: Enrollment was slower than anticipated due to issues operationalizing outpatient follow-up for viremic subjects discharged from hospital prior to study completion, including lack of transportation and delays contracting with home health services to offer home visits. Also, study was terminated prior to meeting enrollment goal due to a decrease in eligible subjects and lack of funding.
Plan to share individual participant data: YES
IPD sharing description: Coded data is anticipated to be shared with outside institutions. Safety data will be shared with the drug manufacturer
IPD time frame: Data is anticiapted to be made available within 3 months of study completion. Safety data, specifically treatment related adverse events, will be shared in real time
IPD access criteria: researchers accessing IPD must be an approved and have a data use agreement in place with Partners Healthcare to access the data
Clinical trial NCT04359511: Efficacy and Safety of Corticosteroids in Oxygen-dependent Patients With COVID-19 Pneumonia
Official title: Efficacy and Safety of Corticosteroids in Oxygen-dependent Patients With COVID-19 Pneumonia in Grand Ouest Interregion France
Acronym: CORTICOVIDHUGO
Sponsor: University Hospital, Tours (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: COMPETITOR TEST (RECOVERY)
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-07-03
Primary completion date: 2020-07-03
Completion date: 2020-07-03
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03041324: Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II
Official title: A Phase I / 2, Multicenter, Open-label, Single-dose, Dose-ranging Study to Assess the Safety and Tolerability of SB-913, a rAAV2/6-based Gene Transfer in Subjects With Mucopolysaccharidosis II (MPS II)
Sponsor: Sangamo Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: All nine subjects dosed in the study have rolled over to the Long-Term Follow-up Study IVPRP-LT01 \[NCT04628871\]
Enrollment: 9.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-05-11
Primary completion date: 2021-05-07
Completion date: 2021-05-07
Limitations and caveats: Due to the limited sample size of 9 subjects, the primary and secondary endpoints could not be analyzed, and this study could not report any conclusions.
Plan to share individual participant data: NO
Clinical trial NCT04203875: Abatacept for Treatment of Recurrent or de Novo Autoimmune Hepatitis
Official title: Abatacept for Treatment of Recurrent or de Novo Autoimmune Hepatitis
Sponsor: Duke University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Lack of eligible study participants.
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-03-09
Primary completion date: 2020-07-23
Completion date: 2020-07-23
Plan to share individual participant data: NO
IPD sharing description: There are no plans to share IPD at this time
Clinical trial NCT04099277: A Study of LY3435151 in Participants With Solid Tumors
Official title: A Phase 1a/1b Study of LY3435151 Administered to Patients With Advanced Solid Tumors
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Study terminated due to strategic business decision by Eli Lilly and Company.
Enrollment: 2.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-10-28
Primary completion date: 2020-03-05
Completion date: 2020-03-05
Baseline population: All randomized participants.
Limitations and caveats: This study was terminated before completion of the dose escalation phase (Part A), due to strategic business decision made by the company.
Plan to share individual participant data: NO
Clinical trial NCT04551300: A Phase 2 Study to Evaluate the Safety and Efficacy of VS-505(AP301) to Treat Hyperphosphatemia in Hemodialysis Patients
Official title: A Phase 2 Study to Evaluate the Safety and Efficacy of Escalated and Fixed Doses of VS-505(AP301) in Comparison With Sevelamer Carbonate to Treat Hyperphosphatemia in Chronic Kidney Disease Patients Receiving Hemodialysis
Sponsor: Shanghai Alebund Pharmaceuticals Limited (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 158.0 (ACTUAL)
Number of arms: 5.0
Start date: 2020-10-13
Primary completion date: 2022-06-30
Completion date: 2022-10-15
Clinical trial NCT02382588: Comparison of Topical 0.15% Gancyclovir Gel Versus 0.3% Hypromellose Gel for the Treatment of Herpes Zoster Keratitis
Official title: A Prospective, Double-masked, Placebo Controlled Comparison of Topical 0.15% Gancyclovir Gel (Zirgan) Versus 0.3% Hypromellose Gel (Genteal Gel; Placebo) for the Treatment of Herpes Zoster Keratitis
Sponsor: Northwestern University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: There were difficulties meeting the enrollment goal within stipulated time frames.
Enrollment: 8.0 (ACTUAL)
Number of arms: 2.0
Start date: 2013-12-10
Primary completion date: 2020-05-11
Completion date: 2020-05-11
Baseline population: Report on Comparison of Topical 0.15% Gancicyclovir Gel vs 0.3% Hypromellose Gel for the treatment of Herpes Zoster keratitis~This study was begun in December of 2013 in order to determine if topical ganciclovir 0.15% was beneficial in the treatment of Herpes Zoster keratitis. Despite the number of years the study was open we were only able to recruit 8 subjects. Data was not summarized due to privacy concerns for participants due to low enrollment The study was closed in May of 2020.
Plan to share individual participant data: YES
IPD sharing description: Once the study is completed study results will be shared with the study subjects.
Clinical trial NCT03769688: Safety and Efficacy of Vaginal Microbiota Transplant (VMT) in Women With Bacterial Vaginosis (BV)
Official title: VMT-01: Safety and Efficacy of Vaginal Microbiota Transplant (VMT) in Women With Bacterial Vaginosis (BV)
Sponsor: Johns Hopkins University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Replaced with different study at another site.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-03-31
Primary completion date: 2023-12-31
Completion date: 2023-12-31
Plan to share individual participant data: NO
Clinical trial NCT02371369: Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)
Official title: A Double-blind, Randomized, Placebo-controlled Phase 3 Study of Orally Administered PLX3397 in Subjects With Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath
Acronym: ENLIVEN
Sponsor: Daiichi Sankyo (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 120.0 (ACTUAL)
Number of arms: 4.0
Start date: 2015-05-11
Primary completion date: 2017-03-27
Completion date: 2021-04-30
Limitations and caveats: Enrollment was stopped on 30 Sep 2016; no new participants received the study drug. After Part 1, those who wished to continue were un-blinded; those on placebo were discontinued.
Plan to share individual participant data: YES
IPD sharing description: De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
IPD time frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
IPD access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
Clinical trial NCT02955823: A Phase II Study of the FIL on Elderly Frail Patients With DLBCL
Official title: A Combination of Lenalidomide and Rituximab as Front Line Therapy for the Treatment of Elderly Frail Patients Evaluated in CGA With Diffuse Large B-cells Non-Hodgkin Lymphoma. A Phase II Study of the Fondazione Italiana Linfomi (FIL)
Sponsor: Fondazione Italiana Linfomi - ETS (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 68.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-09-30
Primary completion date: 2020-09-22
Completion date: 2022-11-24
Plan to share individual participant data: NO
Clinical trial NCT00658021: Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes
Official title: Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes.
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 122.0 (ACTUAL)
Number of arms: 3.0
Start date: 2008-05-30
Primary completion date: 2019-04-18
Completion date: 2020-04-01
Baseline population: The Intent-To-Treat analysis set included all randomized participants.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment.~https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
IPD access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Clinical trial NCT03792295: Multimodal Pain Therapy After Hernia Repair
Official title: The Effect of Multimodal Pain Therapy After Hernia Repair
Sponsor: George Washington University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: no enrollment, reallocation of resources
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-07-01
Primary completion date: 2021-12-01
Completion date: 2022-07-01
Plan to share individual participant data: NO